David Parry
Private Equity Investor at Samsara Biocapital LLC
Profile
Dave joined Samsara in the fall of 2021.
Prior to Samsara, he worked within the Global BD organization at GSK focusing on search, evaluation and due diligence of immunology-focused opportunities for two years.
Prior to his work within Global BD, Dave joined the Discovery Partnerships with Academia (DPAc) Research Unit at GSK, where he worked extensively with multiple US/EU academic institutions to identify and progress early-stage innovation utilizing the capabilities of pharma within a collaborative, milestone-based framework.
Prior to GSK, he was at Portola Pharmaceuticals, working on inflammatory disease and oncology drug discovery/development.
From 1999-2010 he worked at DNAX Research in Palo Alto where led research, drug discovery and early clinical development of small molecule efforts focused on the cell cycle, DNA damage/repair and biopharm targets in the immuno-oncology space.
Dave received his B.Sc.
(Hons) in Biochemistry from The University of Manchester Institute of Science and Technology (UMIST) and a Ph.D.
in Molecular Oncology from The Imperial Cancer Research Fund (ICRF).
David Parry active positions
Companies | Position | Start |
---|---|---|
Samsara Biocapital LLC
Samsara Biocapital LLC Investment ManagersFinance Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California. | Private Equity Investor | 2021-09-30 |
Former positions of David Parry
Companies | Position | End |
---|---|---|
GSK PLC | Corporate Officer/Principal | 2021-09-30 |
PORTOLA PHARMACEUTICALS, INC. | Director/Board Member | 2013-02-28 |
MERCK & CO., INC. | Corporate Officer/Principal | 2010-12-31 |
Schering-Plough Biopharma
Schering-Plough Biopharma Miscellaneous Commercial ServicesCommercial Services Part of Merck & Co., Inc., Schering-Plough Biopharma is a private company that provides pharmaceutical research services. The company is based in Kenilworth, NJ. | Corporate Officer/Principal | 2008-12-31 |
Training of David Parry
University of Manchester Institute of Science & Technology | Undergraduate Degree |
Imperial Cancer Research Fund Trading Ltd. | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
MERCK & CO., INC. | Health Technology |
GSK PLC | Health Technology |
Private companies | 3 |
---|---|
Portola Pharmaceuticals LLC
Portola Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Portola Pharmaceuticals, Inc. engaged in the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation. It offers Andexxa and Bevyxxa medicines. The company was founded by Charles J. Homcy and David R. Philips on September 2, 2003 and is headquartered in South San Francisco, CA. | Health Technology |
Schering-Plough Biopharma
Schering-Plough Biopharma Miscellaneous Commercial ServicesCommercial Services Part of Merck & Co., Inc., Schering-Plough Biopharma is a private company that provides pharmaceutical research services. The company is based in Kenilworth, NJ. | Commercial Services |
Samsara Biocapital LLC
Samsara Biocapital LLC Investment ManagersFinance Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California. | Finance |
- Stock Market
- Insiders
- David Parry